FibroBiologics, Inc. (FBLG)

FibroBiologics Statistics

Total Valuation

FibroBiologics has a market cap or net worth of $21.18 million. The enterprise value is $23.11 million.

Market Cap	21.18M
Enterprise Value	23.11M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025, after market close.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroBiologics has 41.89 million shares outstanding. The number of shares has increased by 18.84% in one year.

Current Share Class	41.89M
Shares Outstanding	41.89M
Shares Change (YoY)	+18.84%
Shares Change (QoQ)	+5.35%
Owned by Insiders (%)	18.35%
Owned by Institutions (%)	11.96%
Float	32.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	24.02
P/TBV Ratio	24.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 12.53.

Current Ratio	0.93
Quick Ratio	0.81
Debt / Equity	12.53
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,462.18

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-88.11%
Return on Invested Capital (ROIC)	-181.37%
Return on Capital Employed (ROCE)	-546.52%
Revenue Per Employee	n/a
Profits Per Employee	-$1.02M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.75% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-81.75%
50-Day Moving Average	0.57
200-Day Moving Average	1.00
Relative Strength Index (RSI)	42.61
Average Volume (20 Days)	903,436

Short Selling Information

The latest short interest is 970,560, so 2.32% of the outstanding shares have been sold short.

Short Interest	970,560
Short Previous Month	917,549
Short % of Shares Out	2.32%
Short % of Float	3.03%
Short Ratio (days to cover)	2.24

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.08M
Pretax Income	-13.22M
Net Income	-13.22M
EBITDA	-15.89M
EBIT	-16.08M
Earnings Per Share (EPS)	-$0.37

Balance Sheet

The company has $8.85 million in cash and $10.78 million in debt, giving a net cash position of -$1.93 million or -$0.05 per share.

Cash & Cash Equivalents	8.85M
Total Debt	10.78M
Net Cash	-1.93M
Net Cash Per Share	-$0.05
Equity (Book Value)	860,000
Book Value Per Share	0.02
Working Capital	-786,000

Cash Flow

In the last 12 months, operating cash flow was -$14.94 million and capital expenditures -$366,000, giving a free cash flow of -$15.30 million.

Operating Cash Flow	-14.94M
Capital Expenditures	-366,000
Free Cash Flow	-15.30M
FCF Per Share	-$0.37

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.84%
Shareholder Yield	-18.84%
Earnings Yield	-62.43%
FCF Yield	-72.26%

Analyst Forecast

The average price target for FibroBiologics is $12.67, which is 2,405.93% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.67
Price Target Difference	2,405.93%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	20.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1